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We reported previously that calpain-mediated
Cdk5 activation is critical for mitochondrial
toxin-induced dopaminergic death. Here, we
report a target that mediates this loss. Prx2, an
antioxidant enzyme, binds Cdk5/p35. Prx2 is
phosphorylated at T89 in neurons treated with
MPP+ and/or MPTP in animals in a calpain/
Cdk5/p35-dependent manner. This phosphory-
lation reduces Prx2 peroxidase activity. Consis-
tent with this, p35/ neurons show reduced
oxidative stress upon MPP+ treatment. Expres-
sion of Prx2 and Prx2T89A, but not the phos-
phorylation mimic Prx2T89E, protects cultured
and adult neurons following mitochondrial in-
sult. Finally, downregulation of Prx2 increases
oxidative stress and sensitivity to MPP+. We
propose a mechanistic model by which mito-
chondrial toxin leads to calpain-mediated
Cdk5 activation, reduced Prx2 activity, and de-
creased capacity to eliminate ROS. Importantly,
increased Prx2 phosphorylation also occurs
in nigral neurons from postmortem tissue from
Parkinson’s disease patients when compared
to control, suggesting the relevance of this
pathway in the human condition.
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by motor symptoms including tremor, mus-
cle rigidity, paucity of voluntary movements, and postural
instability (Hoehn and Yahr, 1967; Lang and Lozano,
1998). The pathological hallmarks of PD are the loss of do-
paminergic (DAergic) neurons in the substantia nigra pars
compacta (SNc) and formation of Lewy bodies (Braak
et al., 2003). The pathogenic process in PD is not clearly
understood. A small portion (less than 10%) of PD patients
have familial forms of the disease, and several PD geneshave been identified (Abou-Sleiman et al., 2006). How-
ever, the vast majority of patients have idiopathic forms
of PD. Parkinsonism can be induced in humans by expo-
sure to the mitochondrial complex 1 toxin, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). This DAergic
toxin results in parkinsonism symptoms indistinguishable
from those of Parkinson’s disease (Burns et al., 1985;
Langston et al., 1983). Experimentally, it induces specific
loss of DAergic neurons in the SNc (Burns et al., 1983)
and produces a profound reduction of striatal dopamine
levels with little alteration in other catecholamine neuro-
transmitter systems (Jonsson et al., 1986). Degeneration
is a consequence of conversion of MPTP by glia to its toxic
metabolite MPP+ followed by specific uptake by DAergic
neurons and presumed targeting of the mitochondria
(Lang and Lozano, 1998).
The cellular consequences of mitochondrial dysfunction
as induced by agents such as MPTP are numerous and
include poor calcium homeostasis and oxidative stress
(Wang and Yuen, 1994). How this dysregulation occurs
and the consequence/management of these stresses are
not fully understood. Recently, and consistent with im-
proper calcium management, we reported that calpains
are activated and required for MPTP-induced death in
adult mice in vivo (Crocker et al., 2003). Calpains are con-
served cysteine proteases regulated by calcium and pos-
sessing diverse biological function (Sorimachi et al., 1997).
This was consistent with earlier reports of elevated calpain
levels in postmortem PD patients (Mouatt-Prigent et al.,
1996). We also showed that calpains were more activated
in PD patients than in control individuals (Crocker et al.,
2003). Importantly, calpain inhibition not only limited
DAergic loss but also improved animal behavior following
toxin treatment (Crocker et al., 2003).
What are the possible downstream targets of calpain
activation? We recently provided evidence that the activa-
tor of Cdk5, p35, may be critical (Smith et al., 2003, 2006).
Cdk5, not thought to be central to the core cell-cycle ma-
chinery, has been implicated in brain function including
neuronal development, neuritic outgrowth, and neuro-
transmitter (dopamine) signaling (Dhavan and Tsai, 2001).
Cdk5 activity is regulated by its activating partners, p35
and p39 (Dhavan and Tsai, 2001). While important for brainNeuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 37
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ate activation of the Cdk5/p35 signal may lead to neuronal
death through pathogenic activation of calpains, which
proteolytically cleave p35 to a more active p25 form (Dha-
van and Tsai, 2001) at least in cultured systems. However,
its functional role in adult degeneration in vivo as well as in
PD was unknown. To this end, we found that Cdk5 plays
an essential role in DAergic loss in vivo (Smith et al., 2003,
2006). For example, we observed that MPTP induced
Cdk5 activation and that inhibition of such activity with
DN Cdk5 expression, Cdk inhibitors, or p35 deficiency
attenuated DAergic death and behavioral deficits asso-
ciated with MPTP treatment (Smith et al., 2003, 2006).
This observation is made more significant by observations
of increased p35 in postmortem PD brains (Nakamura
et al., 1997). It is also entirely consistent with our observa-
tions that calpains are activated, are required for death,
and mediate p35 to p25 cleavage in the MPTP model of
PD (Smith et al., 2003). In support of this, we showed that
inhibition of calpain led to reduced p35 to p25 conversion
and Cdk5 activation (Smith et al., 2006). This suggested to
us a model by which deregulated calcium leads to calpain
activation, inappropriate Cdk5 activity, and DAergic cell
death (Smith et al., 2006). However, the mechanism(s)
by which Cdk5 promotes DAergic loss is still unknown.
To address this, we presently performed mass spectrom-
etry-based interactomics to identify Cdk5-interacting pro-
teins. We identified an intriguing target that has direct
implications for the way in which cells handle oxidative
stress, linking Cdk5 activity with oxidative stress, a com-
mon theme in PD.
Oxidative stress is thought to be a critical mediator of
damage in PD (Przedborski, 2005). Reactive oxygen spe-
cies (ROS) has been observed in the SNc of PD patients
and animal models of PD (Przedborski, 2005). Importantly,
neurons in general have high levels of ROS. Therefore,
systems to handle such stress are of paramount impor-
tance. Peroxidases are a key in this management system.
Three types of peroxidases, peroxiredoxins (Prxs), cata-
lase, and glutathione peroxide (GPx), function to eliminate
H2O2 in mammalian cells (Rhee et al., 2005). In mammalian
cells, six isoforms of Prx were identified. Although Prxs
as a family are relatively ubiquitous, there is some speci-
ficity in regards to cell type and subcellular localization.
For instance, Prx1 is distributed in the cytoplasm of oligo-
dendrocytes and microglia, while Prx2 is located in the
cytoplasm of neurons, and Prx3 is localized in the mito-
chondria of neurons (Jin et al., 2005). Whether and how
Prxs participate in neuronal damage as well as how they
are regulated have yet to be examined.
Presently, we report that Prx2 directly associates with
the Cdk5 kinase complex through p35. In addition, Cdk5
phosphorylates Prx2 at T89 resulting in reduction of Prx2
peroxidase activity and neuronal death in MPP+-treated
cells in vitro and the MPTP mouse model of PD in vivo.
Prx2 activity is functionally relevant since modulation of
Prx2 activity is protective. Importantly, p35/ neurons
have reduced ROS and improved survival consistent with38 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.the above findings. These findings provide a mechanistic
link of how a mitochondrial damaging agent, through cal-
pain-mediated Cdk5 activation and downregulation of an
important antioxidant enzyme, can increase oxidative
load leading ultimately to death.
RESULTS
Identification of Prx2 as a Cdk5-Interacting Protein
We have shown that Cdk5 plays an essential role in loss of
DAergic neurons in the MPTP mouse model of PD (Smith
et al., 2003, 2006). It has also been demonstrated that
Cdk5/p35 exists as macromolecular complexes in brain
extracts, implying that Cdk5 associates with different pro-
teins and functions in different signaling pathways (Lee
et al., 1996). To identify these complexes, we initially uti-
lized bacterially expressed GST-p10, a C-terminal trun-
cated form of p35 containing a 98 amino acid residue N
terminus fused with GST, as a bait to isolate p35-interact-
ing proteins from mouse brain extracts. The interacting
proteins were eluted with 1 M NaCl from GST-immobilized
GSH beads. The eluted proteins were visualized by Coo-
massie blue staining after separation by SDS-PAGE (Fig-
ure 1A). The visualized specific bands were subjected to
protein identification by tandem mass spectrometry. One
of three specifically isolated proteins was found to be Prx2
for which three identified peptides matches were found
(Figure 1B).
Prx2 is an antioxidative enzyme with peroxidase activ-
ity. Importantly, it also contains a conserved motif optimal
for Cdks. Because of these reasons and the potential im-
portance of ROS in PD, we chose this target for our study.
To confirm the interaction between p35 and Prx2, an
in vitro binding assay was carried out utilizing bacterially
expressed proteins. GST-Prx2 or GST alone was incu-
bated with His-tagged p35 and subjected to SDS-PAGE
and western blot analyses using p35 antibody. A specific
interaction was observed only with GST-Prx2 (Figure 1C).
Similarly, a reverse binding experiment was performed
where GST control or GST-Cdk5 was incubated with
His-Prx2 alone or with both His-p35 and His-Prx2.
Specific interaction was only observed with GST-Cdk5,
His-p35, and His-Prx2 coincubation (Figure 1C). Finally,
we also examined whether we could detect interaction
through a means independent of bacterially expressed
proteins by utilizing the yeast two-hybrid interaction as-
say. Consistent with our previous results, we could also
detect interaction between p10 and Prx2 (Figure S1 avail-
able with this article online). These results indicate that
Prx2 specifically interacted with the Cdk5/p35 complex
through its association with p35.
To test whether endogenous Prx2 may exist in a com-
plex with Cdk5/p35 in vivo, immunoprecipitation was
performed using control IgG, p35 (C-19), and Cdk5 (C-8)
antibodies on brain extracts (Figure 1D). The complexes
were then analyzed by SDS-PAGE and Western blot anal-
yses using a Prx2 antibody. Both immunoprecipitates us-
ing either Cdk5 or p35 antibody showed an associated
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p35 Interactor
(A) Isolation of Cdk5-interacting proteins by
affinity purification. Fifty micrograms of bacte-
rially expressed GST and GST-p10 as bait was
immobilized on GSH beads and coincubated
with 1 mg of mouse brain homogenate at 4C
for 3 hr. The eluted proteins were precipitated
by TCA after elution by 1 M NaCl. The precipi-
tates were separated by 10% of SDS-PAGE
then visualized by colloidal Coomassie Blue
staining.
(B) Identification of Prx2 by a tandem mass
spectrometry. The specific bands from GST-
p10 were excised from the stained SDS-
PAGE for mass spectrometric sequencing.
Three underlined peptides were sequenced
by the mass spectrometry and matched to
mouse Prx2.
(C) Confirmation of the interaction between
Prx2 and Cdk5/p35. Two micrograms of bacte-
rially expressed GST and GST-Prx2 was incu-
bated with 10 mg of His-p35 at 4C for 2 hr.
The GST-tagged proteins were retrieved with
GSH beads. The proteins were subjected to
SDS-PAGE and detected using C-19 for p35
by western blots (top panel). Similar to the
above description, GST was incubated with
His-p35 and His-Prx2 or GST-Cdk5 was incubated with His-Prx2 alone or with both His-p35 and His-Prx2 at 4C for 2 hr. The bound proteins
were separated by SDS-PAGE and detected by western blot using anti-Prx2 antibody after retrieval of GST-fused proteins by GSH-Sepharose
(bottom panel).
(D) Association of Prx2 with Cdk5/p35 in vivo. (Top panel) Control IgG, C-19 for p35, and C-8 for Cdk5 were incubated with 500 mg of mouse brain
lysate. Antibodies were isolated by IP beads and the coupled proteins were subjected to SDS-PAGE followed by anti-Prx2 western blot. (Middle
panel) Control IgG or anti-Prx2 (Abcam) as indicated was incubated with mouse brain lysate. Following immunoprecipitation, samples were subjected
to western blot analyses using anti-p35 antibody. (Bottom panel) Control IgG or anti-p35 were incubated with WT (+/+) or p35-deficient (/) mouse
brain lysate as indicated. Following immunoprecipitation, samples were subjected to western blot analyses using anti-Prx2 antibody. Note that all
lanes are from the same gel. However, because of the high intensity of the input-positive control signal, exposure time was reduced for this lane.Prx2 signal by western blot while the control IgG did not.
The reverse interaction assay where immunoprecipitation
with Prx2 preceded western blot analyses for p35 was
also performed using brain extracts. Consistent with the
previous pulldown, a specific interaction between Prx2
and p35 was also observed (Figure 1D). Finally, to further
confirm the specificity of the interaction assay, we also
performed a p35 immunoprecipitation using p35 wild-
type (WT) or knockout brain extracts followed by western
blot analyses utilizing Prx2 antibody. A positive interaction
was only observed with WT brain extract and not with p35-
deficient brains. Taken together, this indicates that endog-
enous Prx2 associates with Cdk5/p35 in vivo.
Prx2 Is a Substrate of Cdk5 and Its Peroxidase
Activity Is Regulated through Phosphorylation
by Cdk5
The consensus sequence of Cdk5 phosphorylation is Pro
(P)-directed Ser (S) or Thr (T) surrounded in the +3 position
by basic amino acids, Arg (R), Lys (K), or His (H) (Songyang
et al., 1996). There is a potential motif in Prx2 containing
Pro-directed Thr, T89PRK, optimal for Cdk5 phosphoryla-
tion. To investigate whether Prx2 is a substrate of Cdk5,
Prx2 and Prx2T89A, a Prx2 mutant in which nonphosphor-ylatable Ala (A) replaced Thr (T), were subjected to in vitro
kinase assay with Cdk5 alone, Cdk5/p35, or Cdk5/p25 ac-
tive complexes. Incubation of bacterially expressed Prx2
or Prx2T89A with Cdk5 alone did not result in any radiola-
bel signal, indicating that the activating binding partner of
Cdk5 was required for phosphorylation. The recombinant
Prx2 was phosphorylated when either p35 or p25 was
present along with Cdk5. In contrast, the recombinant
Prx2T89A showed almost no detectable phosphorylation
(Figure 2A). This indicates that both Cdk5/p35 and Cdk5/
p25 can phosphorylate Prx2 and that almost all the phos-
phorylation occurs on the T89 residue.
To assess the effects of Cdk5-mediated Prx2 phos-
phorylation on peroxidase activity, WT Prx2 was purified
from bacteria. It was then incubated with GST-Cdk5 and
GST-p25 purified from bacteria. Afterwards, phospho-
Prx2 was separated from nonphosphorylated Prx2 by
Q-column. Equal amounts of phosphorylated and non-
phosphorylated Prx2 were then assessed for peroxidase
activity by monitoring the H2O2-dependent oxidation of
NADPH in the presence of thioredoxin (Trx) and Trx reduc-
tase. The peroxidase activity of phospho-Prx2 was 37% of
that of nonphosphorylated Prx2 (Figure 2B). To confirm
isolation and phosphorylation of Prx2 as just described,Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 39
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Cdk5, and Peroxidase Activity of Prx2 Is
Modulated through Phosphorylation
(A) Prx2 is a substrate of Cdk5/p35 and Cdk5/
p25. One microgram of purified His-Prx2 or
His-PrxT89A was incubated with 50 ng of puri-
fied GST-Cdk5, GST-Cdk5/GST-p35, or GST-
Cdk5/GST-p25 and 1 mCi of [g-32P]ATP at
30C for 30 min. The proteins were separated
by SDS-PAGE for autoradiography.
(B) Peroxidase activity of Prx2 is reduced by
phosphorylation. Two hundred micrograms of
His-Prx2 was incubated with 10 mg of GST-
Cdk5/GST-p25 and 10 mM ATP at 30C for
6 hr. The reaction mixture was separated by
Q-column to isolate phospho-Prx2 from Prx2
after clearing GST-tagged Cdk5 and p25 by
GSH-Sepharose. 0.5 mg of Prx2 or phospho-
Prx2 was used for the peroxidase assay at
30C for 10 min. The consumption of NADPH
was measured at 340 nm wavelength by spec-
trophotometer. The data are the mean ± SEM
(n = 3).
(C) Determination of purity of phospho-Prx2
and confirmation of specificity of p-T89 for
phospho-Prx2. One microgram of Prx2 or puri-
fied phospho-Prx2 as isolated in (B) was
probed by western blot analyses using the
p-T89 antibody or a pan-Prx2 antibody.
(D) Peroxidase activity of Prx2T89E is lower
than Prx2. 0.5 mg of purified His-Prx2, His-
Prx2T89A, or His-PrxT89E was assayed for peroxidase activity as described above in (B). The data is the mean ± SEM (n = 4).
(E) Peroxidase activity of Prx2T89A is not affected by Cdk5 phosphorylation. Ten micrograms of purified His-Prx2 or His-Prx2T89A was incubated
with or without GST-Cdk5/GST-p25 (3 mg each) overnight at 30C in the presence of 2 mM DTT. Following dialyses, peroxidase activity was measured
as described in (B). The data are the mean ± SEM (n=3).we generated a phospho-antibody specific for phosphor-
ylated T89 of Prx2. The phospho-T89 (p-T89) antibody
recognized phosphorylated Prx2 but not the nonphos-
phorylated form isolated by Q-column upon western blot
analyses (Figure 2C). A pan-Prx2 antibody was also iso-
lated and shows that total Prx2 levels were approximately
equal between nonphosphorylated and phosphorylated
forms (Figure 2C).
The above results indicate that Cdk5 phosphorylation of
Prx2 results in downregulation of peroxidase activity. To
confirm this and ascertain that this is due to phosphoryla-
tion at T89, we isolated bacterially expressed Prx2, the
Prx2T89A mutant, and a Prx2T89E mutant designed to
mimic phosphorylation. Equal amounts of proteins were
assayed for peroxidase activity. Importantly, the mutant
Prx2T89E resulted in a 66% reduction in peroxidase activ-
ity compared to Prx2. The mutant Prx2T89A on the other
hand was not significantly different from WT (Figure 2D).
Importantly, we would predict that if Cdk5-mediated
phosphorylation of Prx2 at T89 leads to downregulation
of peroxidase activity, the Prx2T89A mutant should not
be responsive to Cdk5 phosphorylation. Consistent with
this notion, phosphorylation of recombinant WT Prx2 but
not the Prx2T89A mutant by Cdk5 in vitro led to reduced
peroxidase activity (Figure 2E). Finally, we also observed
that phosphatase treatment of WT Prx2 previously phos-40 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.phorylated by Cdk5 reversed the decrease in peroxidase
(see Figure S2). Taken together, our data, at least in vitro,
indicate that Cdk5 phosphorylates Prx2 at T89, which
results in reduced Prx2 activity.
Prx2 Plays a Protective Role in Cortical Neurons
Insulted by Neurotoxin MPP+
We next determined whether Prx2 and its phosphorylation
may play a role in neuronal death induced via mitochon-
drial stress by evaluating the effects of MPP+, the active
metabolite of MPTP, on death of cultured cortical neurons.
It is important to note that these cultures are completely
neuronal as evaluated by MAP2 staining (see Figure S3).
We first evaluated the effect of MPP+ on T89 phosphory-
lation utilizing the phospho-specific antibody p-T89 for
phosphorylated Prx2 at T89. Analysis of an MPP+ time
course by western blot indicated a maximal increase in
phospho-Prx2 signal at 24 hr (Figure 3A). This coincided
with the peak in Cdk5 kinase activity measured under the
same conditions (Figure 3B). In the latter assay, immuno-
precipitated Cdk5 from neurons treated by MPP+ at differ-
ent time points was subjected to a kinase assay using
histone H1 as a substrate. The increase in Prx2 phosphor-
ylation at T89 was also observed in cortical neurons
analyzed by immunofluorescence using the same phos-
pho-T89 antibody after MPP+ treatment (Figures 3C, 3D,
Neuron
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upon MPP+ stress in the soma and neurites. This increase
of fluorescence was quantified over a number of neurons
by image analyses, showing a 90% increase in neurites
and 62% increase in the soma. Blocking peptide treat-
ment was used as a control for specificity and shows the
required loss of fluorescent signal. Importantly, levels of
Prx2 did not dramatically change upon MPP+ treatment.
This was observed both with western blot (Figure 3A)
and upon immunofluorescent analyses (Figure 3C). Similar
observations of increased phosphorylation of Prx2 were
also observed in midbrain cultures containing dopamine
neurons exposed to MPP+ (see Figure S4). In addition,
we also observed Prx2 phosphorylation when midbrain
neurons were treated with another mitochondrial toxin,
rotenone (Greenamyre et al., 2003) (see Figure S5).
We next determined whether a reduction in Prx2 activity
accompanied the increase in T89 phosphorylation by an-
alyzing a time course following MPP+ treatment of cortical
neurons. Importantly, Prx2 activity decreased at 24 hr,
opposite to that of T89 Prx2 phosphorylation and Cdk5
activation (Figure 3F). These results suggest that Prx2 per-
oxidase activity is regulated by T89 phosphorylation in
cultured neurons following mitochondrial insult.
To evaluate whether T89 phosphorylation of Prx2 plays
a role in neuronal death induced by MPP+, cortical neurons
were infected with virus expressing Prx2, Prx2T89A, and
Prx2T89E. The viability of the infected neurons was as-
sessed by evaluating nuclear integrity after exposing cul-
tures to MPP+ for 48 hr. Expression of Prx2 and Prx2T89A
significantly protected neurons from death in comparison
to that of GFP and Prx2T89E (Figure 3G). Conversely, we
also evaluated whether downregulation of Prx2 might sen-
sitize neuronal cultures to MPP+ treatment. We designed
three different siRNA sequences to Prx2. The siRNA se-
quences 1 and 2 showed the most significant reduction
in Prx2 levels (Figure 3H). These siRNA sequences sensi-
tized the neuronal cultures to the toxic effects of MPP+
treatment (Figure 3H). Finally, we also examined for ROS
under these conditions by 20, 7’-Dicholororescein diace-
tate (DCF) staining. As shown in Figure 3I, both siRNA
sequences 1 and 2 significantly increased the number of
DCF-positive neurons. Taken together, our results suggest
a model by which a decrease of Prx2 peroxidase activity
mediated through T89 phosphorylation after MPP+ insult
enhances oxidative stress, resulting in neuronal death.
T89 Phosphorylation of Prx2 Is Mediated by Cdk5
in Neurons after MPP+ Treatment
To investigate whether T89 of Prx2 is phosphorylated in
neurons by Cdk5, lysates from WT and p35/ neurons
treated with MPP+ were analyzed by western blot. Ab-
sence of p35 led to a significant decrease of phosphoryla-
tion of Prx2 at T89 (Figure 4A). It is important to note, how-
ever, that this reduction was not absolute, suggesting
that, at least in the present in vitro paradigm, other activa-
tors of Cdk5 such as p39 might also be present. It might
also be due to the actions of other kinases. Prx2 levelswere not observed to vary between WT and p35/ neu-
rons with or without MPP+ treatment. To further confirm
this reduction in phospho-Prx2 signal with p35 deficiency,
we carried out immunofluorescent analyses. In p35/
neurons, the increase in phospho-T89 signal observed
upon MPP+ treatment in WT neurons was significantly
reduced (Figure 4B). Consistent with this observation,
similar inhibition of Prx2 phosphorylation was observed
with treatment of the Cdk inhibitor Roscovitine, but not
with the GSK3 inhibitor lithium (see Figure S6). These
data indicate that the phosphorylation of Prx2 at T89 in
neurons following MPP+ insult is significantly dependent
upon Cdk5 activity. Next, we examined peroxidase activ-
ity of Prx2 in WT and p35/ neurons following MPP+
treatment. The data clearly showed that Prx2 peroxidase
activity was decreased following MPP+ treatment in WT
neurons. However, this reduction did not occur in p35/
neurons (Figure 4C). This indicates that peroxidase activ-
ity of Prx2 is regulated via phosphorylation by Cdk5.
These data also suggested that p35/ neurons should
show reduced oxidative stress and resistance to MPP+-in-
duced neuronal death. To test this, ROS levels were mea-
sured utilizing DCF. ROS was significantly increased in
WT neurons upon MPP+ exposure as measured by both
average intensity (54% increase) (Figures 4E and 4F) and
number of DCF-positive neurons (34% increase) (data
not shown). In contrast, p35/ neurons showed reduced
ROS levels upon MPP+ treatment (35% decrease average
density, Figure 4F; 25% decrease total number of cells,
data not shown) when compared to WT littermate con-
trols. p35/ neurons were also substantially protected
from MPP+-induced death when compared to WT litter-
mate control neurons (Figure 4D). Finally, based upon
our previous observations that calpain-mediated activa-
tion of Cdk5 is important for neuronal death (Smith et al.,
2006), we would predict that calpain inhibition should
also block Prx2 phosphorylation. Consistent with this, co-
treatment of MPP+-exposed neuronal cultures with the
calpain inhibitor PD150606 (Sedarous et al., 2003; Wang
et al., 1996) led to decreased Prx2 signal as measured
by immunofluorescence analyses (Figures 4G and S7).
Taken together, our data indicate that Cdk5 kinase activity
has a critical role in the reduction of Prx2 peroxidase activ-
ity through phosphorylation of Prx2 at T89 following MPP+
insult and that this is a contributing factor to ROS increase
and the ensuing neuronal death.
Prx2 Prevents the Loss of DAergic Neurons
in the SNc in MPTP Mouse Model of PD
The phosphorylation of Prx2 at T89 by Cdk5 has a func-
tional role in neuronal death in the MPP+-induced cell
death model. These data led us to further investigate the
effects of Prx2 on neuronal death in an in vivo mouse
model of PD. We employed the MPTP mouse model of
PD to assess roles of Prx2 in the loss of DAergic neurons.
We first determined the effects of expression of WT Prx2
and its mutants, Prx2T89A and Prx2T89E, on survival of
DAergic neurons following MPTP administration. TheseNeuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 41
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(A) Increase of phospho-Prx2 after MPP+ insult. Cultured cortical neurons were treated with 20 mM MPP+. The treated neurons were harvested at
different time points, 6, 12, 24, 48, or 72 hr after MPP+ treatment. Forty micrograms of cell lysate was analyzed by western blot analyses utilizing
p-T89, anti-Prx2, C-19 for p35, C-8 for Cdk5, or anti-b-actin antibodies. Similar results were observed in three independent experiments.
(B) Increase of Cdk5 kinase activity in neurons after MPP+ treatment. Neurons were treated as above described. Cdk5 was isolated from 50 mg of cell
lysate by immunoprecipitation using the C-8 antibody and was incubated with 0.5 mCi of [g-32P]ATP at 30C for 30 min using histone H1 as a substrate.
The proteins were separated by SDS-PAGE for autoradiography. The density of autoradiographic bands was normalized from three experiments and
is presented as mean ± SEM.
(C) Increase of phospho-Prx2 in neurons by immunofluorescent staining. After 24 hr treatment by MPP+, neurons were fixed by 4% paraformalde-
hyde. (a–d) Neurons were incubated with p-T89 antibody and coincubated with the appropriate phosphorylated peptide sequence used to produce
the antibody (c and d) or the control nonphosphorylated peptide sequence (a and b). (e–h) Neurons were fixed as above and stained with our pan-Prx2
antibody without (e and f) or with (g and h) a quenching peptide used to produce the antibody as control. The images were captured by fluorescent
microscopy.
(D and E) Distribution of phospho-Prx2 in neurons treated by MPP+. The fluorescent signal in soma (D) or dendrites (E) was measured from 200
neurons through image analysis. The data are the mean ± SEM.
(F) Downregulation of Prx2 peroxidase activity after MPP+ treatment. Prx2 was isolated from cultured neurons treated with MPP+ for the indicated
times using a monoclonal anti-Prx2 antibody obtained from Abcam. Peroxidase activity was measured as described above. The data are the
mean ± SEM (n = 3).42 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.
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neurons using an adenoviral-mediated gene delivery ap-
proach as we have previously performed (Crocker et al.,
2001, 2003; Kalia et al., 2004; Kim et al., 2005; Smith et al.,
2003). Protein expression of adenoviral Prx2 and its
mutant was verified by western blot analysis (Figure 5B).
We found that expression of Prx2 and Prx2T89A resulted
in significant DAergic neuroprotection following MPTP
treatment when compared with the contralateral un-
treated side or with GFP-injected control animals as ana-
lyzed by counting the number of tyrosine hydroxylase (TH)
positive neurons (Figures 5A and 5B). In contrast, expres-
sion of Prx2T89E showed similar effects to GFP controls
(Figures 5A and 5B). As an independent assessment of
survival, we also examined for the number of neurons in
the SNc region by cresyl violet staining. This also ensures
that loss of neurons by MPTP treatment is not simply due
to loss of TH expression. Our cresyl violet analysis was
similar to that of TH assessment (Figure 5C). These data
indicate that Prx2 can modulate DAergic neuron survival
in the SNc following MPTP administration and suggest that
the T89 regulatory site may be important in this DAergic
cell death process.
Cdk5-Mediated Phosphorylation of Prx2 at T89
Plays a Pivotal Role in DAergic Neuron Damage by
Regulation of Prx2 Peroxidase Activity in an MPTP
Mouse Model of PD
The above in vivo evidence only demonstrates that Prx2
could potentially be important in the MPTP model. To fur-
ther support this, we examined whether endogenous Prx2
may be modulated at T89 following MPTP treatment. Ac-
cordingly, the SNc extracts obtained from mice treated
with MPTP for various times were subject to western blot
analyses. As shown in Figure 6A, Prx2 phosphorylation
increased following MPTP treatment, reaching the highest
level of phosphorylation at 3 days following injected
MPTP. To determine whether the phosphorylation of
Prx2 at T89 is mediated by Cdk5, the SNc lysates from
p35/ mice or WT littermate controls were treated with
MPTP and analyzed 3 days post-treatment. The level of
phosphorylated Prx2 in p35/ mice was significantly
less than that in WT mice after MPTP treatment (Figure 6B).
To further confirm the increase in the level of phosphory-
lated Prx2 in DAergic neurons in SNc of MPTP-treated
mice, we assessed Cdk5-phosphorylated Prx2 by immu-nofluorescence analyses. Phosphorylated Prx2 was
clearly observed in DAergic neurons in the SNc of WT
mice treated with MPTP but not substantially observed
in that of p35/ mice (Figure 6C). We quantified the aver-
age fluorescent signal from TH-positive neurons by image
analyses. As shown in Figure 6D, the fluorescent signal of
phospho-Prx2 in WT SNc increased approximately 30%–
50% in comparison to untreated WT controls or treated
and untreated p35/ mice.
To examine whether the peroxidase activity of Prx2 is af-
fected in the MPTP mouse model of PD, Prx2 was isolated
from p35/ SNc or WT littermate controls with and with-
out MPTP treatment and assayed for activity. Prx2 isolated
from WT mice treated by MPTP showed a significant
decrease in peroxidase activity in comparison to untreated
WT controls. In contrast, p35/ animals did not show this
reduction following MPTP treatment (Figure 6E). Finally,
we have previously shown that calpains are central for
Cdk5 activation (Smith et al., 2006). Consistent with this,
adenoviral-mediated expression of the calpain inhibitor
calpastatin blocks increase in phospho-Prx2 following
MPTP treatment in vivo (Figure S8). Taken together, these
data indicate that calpain-mediated Cdk5 activation medi-
ates phosphorylation and reduction of Prx2 activity in an
in vivo model of PD and that this activity plays an important
role in the death of DAergic neurons.
Relevance to Human PD
While the above evidence strongly implicates the impor-
tance of Prx2 in the MPTP model of PD, we directly exam-
ined its potential relevance to human PD. Accordingly, we
first examined the phospho-Prx2 signal in human PD post-
mortem samples and controls. The equivalent T89 site is
also present in human Prx2. As shown in Figure 7, nigral
DAergic neurons from human midbrain PD and control
samples were clearly detected by the presence of neuro-
melanin, granular brown pigmented regions detectable
even without staining (see arrowheads in Figures 7A and
7B). When stained using phospho-Prx2 antibody and
DAB visualization, little or no signal was detected in the
perikarya of dopamine neurons from control midbrain
samples. However, significant staining (black color) was
observed in soma of dopamine neurons from PD patients
(see arrow, Figure 7A). Staining in the region of neurons
that resemble dopamine neurons in size and location but
that did not contain neuromelanin was also observed in(G) Prx2 protects neuron form death after MPP+ treatment. Cortical neurons were infected with virus expressing GFP alone or along with Prx2,
Prx2T89A, or Prx2T89E and cultured for 3 days. The cells were exposed to MPP+ for 48 hr and neuronal survival was evaluated by assessing nuclear
integrity of GFP-positive neurons. The data are the mean ± SEM (n = 3). Similar results were obtained when equivalent constructs were transfected
(data not shown).
(H) Downregulation of Prx2 by siRNA oligonucleotide treatment sensitizes cortical neurons to MPP+ treatment. Three independent siRNA sequences
(s1/siRNA1, s2/siRNA2, s3/siRNA3) and a control sequence (c/siRNAc) were evaluated for their ability to downregulate endogenous Prx2 levels in
cortical neurons as described in Experimental Procedures (top panel). (Bottom graph) Transfected cultures were then assayed for survival following
48 hr MPP+ treatment by MTT assay. The data are the mean ± SEM (n = 3).
(I) Downregulation of Prx2 by siRNA oligonucleotide treatment increases ROS levels following MPP+ treatment. (Top panel) Representative DCF fluo-
rescence in control (siRNAc) or siRNA1 or siRNA2 oligonucleotide-treated cultures after treatment with 20 mM MPP+ for 24 hr under a fluorescent
microscope. (Bottom graph) Quantification of the number of DCF fluorescence-positive cells in cells treated as above. Random fields were analyzed
for the number of DCF-positive neurons. The data are the mean ± SEM (n = 4).Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 43
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MPP+
(A and B) Cdk5 phosphorylates Prx2 in neurons treated by MPP+. (A)
Neurons from WT or p35/ embryos were treated with MPP+ insult
for 24 hr. The cell lysates were subjected to SDS-PAGE and p-T89
western blot analyses. The membranes were then stripped and re-
probed with anti-Prx2, C-19 for p35, C-8 for Cdk5, or anti-b-actin.
The bottom panel shows densitometric values of phospho-Prx2
relative to Prx (p-T89/total Prx2*100). Each value is the mean ± SEM
(n = 3). (B) Likewise, cultures as indicated were subjected to immuno-
fluorescent staining utilizing the p-T89 antibody. Similar results were
obtained in three independent experiments.
(C) Phosphorylation of Prx2 at T89 by Cdk5 reduces peroxidase activ-
ity. Cortical cultures from WT or p35/ embryos were treated with
MPP+ for 24 hr as described above. Peroxidase activity assay was car-
ried out also as described above. The data are the mean ± SEM (n = 3).
(D) p35/ neurons are resistant to MPP+-induced death. Neurons
from WT or p35/ embryos were exposed to MPP+ for 48 hr. The
viability of neurons was measured by MTT assay. The survival percent-
age was obtained by comparing value from the MPP+-treated neurons
to that of the nontreated neurons in either p35/ or WT neuronal
cultures. The data are presented as mean ± SEM (n = 3).
(E and F) The role of Cdk5/p35 in MPP+-induced ROS. (E) Representa-
tive DCF fluorescence in WT and p35/ neurons after treatment with
20 mM MPP+ for 24 hr under a fluorescent microscope. (F) Quantifica-
tion of DCF fluorescence signal in WT and p35/ neurons either44 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.PD samples. Staining of neuritic processes was observed
in both control and PD samples. The number of phospho-
Prx2-positive dopamine neurons was then quantified from
five PD and six control samples. As shown in Figure 7C,
a significant increase in phospho-Prx2-positive neurons
was observed in PD patient samples when compared to
controls.
Finally, we examined whether familial PD genes may im-
pact Prx2 phosphorylation. The PD gene, dj-1, has also
been linked to management of ROS (Bonifati et al., 2003;
Kim et al., 2005). Interestingly, DJ-1 expression blocked
Prx2 phosphorylation in neurons treated with MPP+ (Fig-
ure S6C). Modulation of another PD gene, pink1 (Valente
et al., 2004), however, did not affect Prx2 phosphorylation,
suggesting some specificity in the way PD genes impact
Prx2 phosphorylation (Figure S6D). Taken together, our
human patient data as well as that with DJ-1 further sup-
port the importance of Prx2 in PD.
DISCUSSION
ROS are generated as a result of normal metabolism
(Adam-Vizi, 2005). However, generation of excessive oxi-
dative load beyond a cell’s homeostatic capacity can be
deleterious. Mitochondrial dysfunction and excess ROS
have been strongly implicated in the pathogenesis of PD
(Jenner, 1998; Przedborski, 2005). However, how these
events are initiated, are regulated, and interact to promote
neuronal death is not completely clear. Recently, we dem-
onstrated that calpain-mediated Cdk5 activation plays an
essential role in DAergic loss in the MPTP model of PD
(Crocker et al., 2003; Smith et al., 2003, 2006). These find-
ings were important since they provided a plausible link
between the actions of a mitochondrial damaging agent
(MPTP) and activation of a pathogenic calcium-depen-
dent process (calpain activation) consistent with known
deregulation of calcium homeostasis in PD. However,
the manner by which Cdk5 regulates downstream patho-
genic events was not completely known. Presently, we
identified a novel Cdk5 target, Prx2, an antioxidant en-
zyme with peroxidase activity (Rhee et al., 2005). We pro-
vide evidence that Prx2 is a physiological substrate of
Cdk5. Cdk5 activation downregulates Prx2 peroxidase
activity in PD models of death both in culture and in ani-
mals. Modulation of Prx2 activity also regulates neuronal
loss. These data provide a mechanistic link of how the mi-
tochondrial damaging agent MPTP leads to nigral loss
by Cdk5 activation, phosphorylation/inactivation of an
treated or untreated with MPP+. Random fields were analyzed for av-
erage fluorescence intensity. The data are the mean ± SEM (n = 4).
(G) Calpain inhibitors block increase in MPP+-induced phospho-Prx2
signal. Cortical neuronal cultures were untreated or treated with
20 mM MPP+ and/or the calpain inhibitor PD150606, as indicated. Cul-
tures were fixed and stained for phospho-Prx2 and Hoechst. For rep-
resentative pictures, please see Figure S7. The fluorescent signal in
soma was measured by image analyses from 45 neurons in 3 random
fields. The data are presented as mean ± SEM.
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following MPTP Administration
(A) The adenoviruses (2 ml, 13 107 particles per
ml) expressing Prx2, Prx2T89A, and Prx2T89E
were injected directly into the striatum of ani-
mals 7 days before initiation of MPTP treat-
ment. A GFP-expressing virus was used as
a control. Brains were sectioned into 14 mm
slices for TH DAB staining. Representative pic-
tures of the ipsilateral side of animals injected
with the indicated virus and treated with
MPTP were shown.
(B) Quantification of the number of DAergic
neurons from ipsilateral or controlateral for the
indicated treatment groups are shown. The
data are presented as mean ± SEM (n = 4–5/
group). Expression of Prx2, Prx2T89A, and
Prx2T89E in the SNc extracts was confirmed
by western blot analyses using a pan-antibody
for Prx2.
(C) Quantitation of neurons in the SNc region
by cresyl violet staining. The data are pre-
sented as mean ± SEM (n = 4/group).important antioxidant enzyme, and consequent increase
in oxidative load (see Figure 8). The observation of in-
creased Prx2 phosphorylation in human PD tissue as
well as modulation by DJ-1 also indicates the potential im-
portance of this pathway in human PD.
Prx2 Interacts with Cdk5/p35 Complexes
and Is a Substrate of Cdk5
Our results demonstrate that Cdk5/p35 interacts with
Prx2. Prx2 is a member of the Prx family that contains at
least six members. The identification of the Prx2 form as
an interacting partner is particularly relevant since Prx2
is localized to neurons, including the DAergic neurons of
the SNc (Jin et al., 2005; Sarafian et al., 1998). This is, in
turn, consistent with known DAergic functions of Cdk5,
particularly in models of PD as reported previously (Smith
et al., 2003, 2006). In contrast, Prx1, also localized to the
cytoplasm, is distributed in oligodendrocytes and micro-
glia (Jin et al., 2005). These results, particularly in vivo,
point to a neuron-specific Cdk5-Prx pathway of ROS
management rather than a non-cell-autonomous mode
of action regulated by other brain cell types such as glia.
It is important to point out that this does not exclude the
potential importance of other Prx members in neuronal
loss. For example, Prx3, a mitochondrially localized en-
zyme (Watabe et al., 1994), also has potential Cdk5 sites.
It will be interesting to determine whether this member
might also play a Cdk5-dependent role in mitochondrial
stress-induced death.
Our initial results indicated that the N-terminal portion of
p35 was sufficient to bind to Prx2. However, it is important
to note that both p35 and p25 can efficiently phosphory-
late Prx2, at least in vitro. This suggests that stable binding
to a Cdk5/p35 complex per se mediated by the p10 frag-
ment is not required for efficient phosphorylation. Wespeculate that the p10 portion may be an important regula-
tory domain that regulates how efficiently p35 or Cdk5/p25
complexes may phosphorylate Prx2. Careful analyses will
have to be performed to further study this interesting obser-
vation. Nonetheless, our results indicate not only that both
Cdk5 complexes phosphorylate Prx2 on T89, but also that
this modification significantly downregulates its activity.
Under basal conditions, p35 is abundantly localized to
the inner cellular membrane, through a myristoylation an-
chor (Patrick et al., 1999). Appropriate activation of this
form of Cdk5/p35 is the presumptive ‘‘normal’’ activity of
this complex. However, p35 can be converted to a patho-
genic p25 form by calpain-mediated cleavage (Lee et al.,
2000; Smith et al., 2003, 2006). This results in a more sta-
ble active Cdk5 activator as well as the potential to be mis-
localized to the nucleus (Gong et al., 2003; O’Hare et al.,
2005). One suggested nuclear target of the Cdk5/p25
complex is Mef2, which we and others have shown is im-
portant in models of oxidative stress in vitro (Gong et al.,
2003) and following MPTP in vivo (Smith et al., 2006).
Cytoplasmic Cdk5 activity might also be pathogenic.
For example, a portion of p25 could also be localized to
the cytoplasm, and cytoplasmic targets such as tau have
been previously proposed for Cdk5 particularly in models
of Alzheimer’s disease (Patrick et al., 1999). In this regard,
we have identified an important cytoplasmic target of
Cdk5 that could be regulated by either Cdk5/p35 or Cdk5/
p25 complexes. The observation that Cdk5/p25 com-
plexes efficiently phosphorylate Prx2 on T89, however,
is consistent with a pathogenic role of this complex.
Cdk5-Mediated Prx2 Downregulation in PD
and Oxidative Stress
The identification of Prx2 as a target of Cdk5 is particu-
larly relevant since DAergic neurons are thought to beNeuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 45
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(A) Phosphorylation of Prx2 at T89 is increased after MPTP administration. The SNc extracts were obtained from animals treated with MPTP for the
indicated times. (Bottom panel) The SNc lysates were subjected to SDS-PAGE and western blot probed as indicated using p-T89, anti-Prx2, and anti-
b-actin antibodies. The top panel shows densitometric values of phospho-Prx2 relative to Prx (p-T89/total Prx2*100). Each value is the mean ± SEM
(n = 3).
(B) Prx2 is a substrate of Cdk5 complexes in DAergic neurons from MPTP-administrated mice. (Bottom panel) The SNc lysates from WT or p35/
mice 3 days following MPTP or saline administration were analyzed by western blot analyses using p-T89, anti-Prx2, anti-p35 (C-19), anti-Cdk5 (C-8),
and anti-b-actin antibodies. The top panel shows densitometric values of phospho-Prx2 relative to Prx (p-T89/total Prx2*100). Each value is the
mean ± SEM (n = 3).
(C) Increased phospho-Prx2 is colocalized with TH-positive neurons. The sections from WT or p35/ mice were analyzed 3 days following MPTP or
saline treatment. Sections were double-stained using p-T89 antibody (green) and anti-TH monoclonal (red) antibody for 24 hr at 4C. The sections
were incubated with Alex-488-conjugated antibody specific for rabbit IgG and Alex-594-conjugated antibody for mouse IgG for 3 hr at room temper-
ature. The sections were visualized by fluorescent microscopy.
(D) The fluorescent signals from the p-T89 labeling (C) were quantified densitometrically by imaging analysis. Three sets of animals (n = 1 animal/treat-
ment group/set) were individually stained and analyzed by densitometric analyses. 40–50 TH-positive neurons for each animal (over 3–6 slides/
animal) were measured for p-T89 signal. This value was then averaged. Within each set of animals, the average value for each treatment group
was normalized to the WT MPTP value. The values were then averaged for all three sets of animals for an n = 3 (mean ± SEM).
(E) Downregulation of peroxidase activity of Prx2 is mediated by Cdk5 in mice administrated by MPTP. Prx2 was isolated from 50 mg of SNc lysates
from WT or p35/ mice obtained 3 days following treatment with saline, or MPTP was analyzed for peroxidase activity. The data are presented as
mean ± SEM (n = 3).46 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.
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Cdk5 Phosphorylation of Prx2 in Neuron Lossparticularly susceptible to oxidative stress (Smythies and
Galzigna, 1998). There are several lines of evidence that
support a link between ROS and PD. For example, ROS
levels are very high in PD patients (Jenner, 1998; Przed-
borski, 2005). Numerous enzymes that produce ROS
have been implicated as critical in in vivo models of PD
(Przedborski, 2005). Damaging ROS has also been shown
to occur in animals following exposure to mitochondrial
poisons (Ara et al., 1998; Schapira, 2001). Importantly,
the mitochondria, a major source of oxidative stress, par-
Figure 7. Prx2 Phosphorylation in Human PD
Phosphorylation of Prx2 is increased in human PD. Human substantia
nigra obtained from (A) PD and (B) control individuals. Sections were
immunostained using p-T89 Prx2 antibody and visualized by DAB
staining. Neuromelanin pigment indicative of dopamine nigral neurons
is present as punctate brown staining (arrowheads) while the phospho-
Prx2 signal shows as black staining in the soma (arrows). Two exam-
ples of phospho-Prx2 positive (A) and negative (B) neurons are labeled
with arrows/arrowheads. (C) Quantitation of phospho-Prx2-positive
neurons in PD (n = 5) and control (n = 6) individuals are shown (mean
± SEM). *p < 0.05 (Student’s t test).ticipates in PD pathogenesis (Przedborski, 2005). Consis-
tent with this notion, familial forms of PD have been asso-
ciated with mitochondrial dysfunction. Indeed, the familial
PD gene dj-1 is thought to possess direct antioxidant
functions (Bonifati et al., 2003; Canet-Aviles et al., 2004;
Dawson and Dawson, 2003; Kim et al., 2005; Martinat
et al., 2004; Shendelman et al., 2004).
Our evidence suggests that regulation of Prx2 is impor-
tant in a toxin model of PD. For example, alteration of Prx2
levels modulates death both in vitro and in vivo following
MPP+/MPTP. It must be noted, however, that there are
limitations to relating the in vivo MPTP model to PD and
caution must be observed in making any direct compari-
sons to the human condition. For example, the relatively
acute toxic nature of the MPTP model might not reflect
accurately what occurs in the idiopathic PD. Accordingly,
to support our MPTP data, we also report that phosphor-
ylation of Prx2 also occurs in the nigral region of PD pa-
tients. This is consistent with the relevance of our findings
to the human condition. However, standard and important
caveats to interpreting any postmortem data apply here as
well.
Using the MPTP model as an important first step in
understanding the nigral degenerative process, we have
identified how Prx2 is modulated to promote death follow-
ing exposure to this mitochondrial toxin. We have shown
previously that Cdk5 is hyperactivated and plays a major
functional role in dopamine loss in the MPTP model (Smith
et al., 2003). It is likely that Cdk5 acts to modify several
downstream targets. For example, we had also previously
shown that Cdk5 targets the nuclear transcription factor
and survival factor Mef2 on a site known to suppress its
activity (Smith et al., 2006). However, cytoplasmic targets
may also be critical. We believe that Prx2 is one such im-
portant cytoplasmic factor. This is supported by our data
showing that Prx2 is phosphorylated at T89 both in vitro
and in vivo following MPP+/MPTP and that this is associ-
ated with a decrease in peroxidase activity. In support ofFigure 8. Model of Cdk5-Mediated
DAergic Loss in MPTP Mouse Model of PD
Cdk5 kinase activity is activated by mitochon-
drial stress induced by MPP+, a metabolite of
MPTP. Activated Cdk5 regulates DAergic loss
through phosphorylation of cytoplasmic sub-
strate Prx2 to inhibit its antioxidative ability and
phosphorylation of nuclear target Mef2 to inhibit
Mef2 prosurvival function.Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 47
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Prx2T89E does not protect neurons from mitochondrial in-
sult, whereas WT or a mutant lacking the T89 phosphory-
lation site effectively promotes survival. Most importantly,
Prx2 phosphorylation is dependent on the Cdk5 complex
since p35-deficient animals, which are resistant to death
induced by MPP+ or MPTP, have reduced Prx2 phos-
phorylation and Prx2 peroxidase activity. It is important
to highlight that, in addition to peroxidase activity, Prx2
is also thought to possess some chaperone activity at
least in cell lines (Moon et al., 2005). The relevance of
this in the present context is not completely known. How-
ever, we have determined that the higher molecular weight
complexes of Prx2 indicative of its chaperone activity do
not change following MPP+ insult, suggesting that its
chaperone activity may not be relevant in this model
(D.Q. and D.S.P., unpublished results). Finally, as men-
tioned previously, whether other members of Prx may be
important in nigral degeneration is unknown. Intriguingly,
Prx1 has been shown to be phosphorylated by cell-cycle
Cdk members (Yang et al., 2002). The latter has been
also implicated in neuronal death (Bu et al., 2002; Busser
et al., 1998; McShea et al., 1997; Nguyen et al., 2003;
Osuga et al., 2000; Rashidian et al., 2005; Rideout et al.,
2003; Wang et al., 2002; Zhang et al., 2004). Therefore,
whether/how other Prx members are regulated by Cdk
members will be of further interest.
In summary, we have uncovered an important mecha-
nism by which calpain-mediated Cdk5 activation regulates
DAergic neurodegeneration in an MPTP model of PD via
downregulation of Prx2 peroxidase activity. We propose
that this loss significantly enhances the ROS environment
and leads to DAergic neuron loss (Figure 8). This central
pathway in addition to other pathways mediated by addi-
tional calpain or Cdk5 targets ultimately lead to nigral de-
generation in response to MPTP (Figure 8). These findings
are particularly relevant to human PD since both deregu-
lated Cdk5 and increased ROS have been shown in the
human PD condition (Jenner, 1998; Nakamura et al., 1997;
Przedborski, 2005). Furthermore, we presently, show that
phosphorylated Prx2 is increased in human PD patients
and that Prx2 phosphorylation is also modified by dj-1, a
known PD gene (Bonifati et al., 2003). How the latter links
to Prx2 phosphorylation will be of great interest in future
studies. Taken together, our findings suggest that strate-
gies to modulate Prx2 activity serve as beneficial targets
for treatment of PD. This is of particular importance since
Cdk5 is thought to have normal beneficial roles in neurons
(Li et al., 2002) and modulating a relevant downstream tar-
get rather than Cdk5 directly may be a better therapeutic
strategy with regard to this pathway.
EXPERIMENTAL PROCEDURES
Animals
Eight-week-old male C57BL/6 mice (22–28 g; Charles River Laborato-
ries, USA) were used for MPTP experiments. All animal experiments
conformed to the guidelines set forth by the Canadian Council for48 Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc.the Use and Care of Animals in Research (CCAC) and the Canadian
Institutes for Health Research (CIHR) and had approval from the Uni-
versity of Ottawa Animal Care Committee.
Antibodies
The following antibodies were utilized: Tyrosine hydroxylase (TH) (Im-
munostar, USA), C-8 for Cdk5 (Santa Cruz, USA), C-19 for p35 (Santa
Cruz, USA), b-Actin (monoclonal, Sigma, Canada), Prx2 (monoclonal,
Abcam, UK), and Alex-labeled secondary antibodies (Invitrogen, Can-
ada). Prx2 and phospho-Prx2T89 polyclonal antibodies were gener-
ated and initially purified from rabbit using standard protocols from
Biogenes (Berlin, Germany) by immunization with carrier protein-con-
jugated phosphopeptide, LAWINpTPRKEGGLG. The phospho-Prx2
antibody p-T89 was obtained by first purifying the serum using the
phosphorylated peptide. The pan-Prx2 antibody was obtained using
the nonphosphorylated peptide. The phospho-specific antibody was
further purified by adsorbing onto bacterially expressed and purified
GST-Prx2 to remove any remaining crossreactivity to nonphosphory-
lated Prx2. MAP2 was obtained from Santa Cruz (H-300; 1:300).
Isolation of p35-Binding Proteins
The assay was carried out as previously described (Qu et al., 2002).
Mass Spectrometry
The specific bands on GST-p10 lane were subjected for protein iden-
tification by a tandem mass spectrometry as previously described
(Shevchenko et al., 1996; Wilm et al., 1996).
Fusion Proteins
All GST and His fusion proteins were expressed in E. coli and affinity
purified using GSH-beads and Ni-NTA Agarose (QIAGEN Inc, Canada)
as per manufacturer’s instruction.
In Vitro Binding Assay
The binding assay was performed as previously described (Qu et al.,
2002).
Yeast Two-Hybrid
Plasmid construction: Plasmids were constructed using standard sub-
cloning procedures. Briefly, an NcoI/SalI digest of p10 and an NcoI/
BamHI digest of Prx2 were subcloned into NcoI/XhoI-digested
pAS2-1 (Clontech, Canada) and Nco/BamHI-digested pACT2 (Clon-
tech), respectively. Yeast two-hybrid screening (Clontech) pAS2-
p10 and pACT2-Prx were transformed into Y187 and AH109 strains
by the LiAc method (Ito et al., 1993) and plated onto SD-Trp and
SD-Leu plates, respectively, as previously described (Mao et al.,
2004). Plates were incubated for 5 days at 30C. Resultant colonies
were mated and selected on SD-LeuTrpHis for 3–7 days at 30C.
Immunoprecipitation
Samples were harvested in lysis buffer (50 mM Tris-HCl [pH 7.4],
100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.2% Triton X-100) supple-
mented with protease inhibitors. Immunoprecipitations (IPs) were
performed through incubation of antibodies with lysates overnight
followed by incubation with anti-rabbit or anti-mouse Ig IP beads
(eBiosciences, USA) at 4C for 1 hr. The beads were washed three
times by lysis buffer without protease inhibitors.
Neuronal Cultures
The primary culture of mouse cortical neurons was carried out as de-
scribed previously (Fortin et al., 2001; Xiang et al., 1996). Alternatively,
for midbrain neuronal cultures, the whole midbrain, without meninges
and blood vessels, was collected from embryos aged 13.5 days ges-
tation and processed as above and as similarly described (Liu et al.,
2000). Cultures were subject to 20 mM MPP+ or rotenone (as indicated
in text). In select experiments, neurons were also pretreated with the
calpain inhibitor PD150606 (Calbiochem, Canada), the Cdk inhibitor,
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Cdk5 Phosphorylation of Prx2 in Neuron Lossroscovitine (Sigma, Canada), or lithium (BDH, Canada) for 3 hr and then
cotreated with 20 mM MPP+. For survival using p35/ neurons, litter-
mate controls, or siRNA knockdowns, the MTT assay was utilized as
per manufacturer’s instruction (Sigma, Canada). For transfection or in-
fection cultures, the alternative strategy described below was utilized
since only a small percentage of the neurons in culture were targeted.
ROS Imaging
Cortical neurons were incubated with 10 mM DCF for 20 min at 37C
and washed three times with NB medium. The fluorescence signal of
oxidized DCF was observed by an inverted fluorescent microscope
equipped with a 100 W xenon lamp and filter (for oxidized DCF, exci-
tation = 488 nm and emission = 510 nm). At least four random fields
were quantified for DCF-positive cells and/or average intensity by
image analyses.
Infection and Calcium Phosphate Transfection
of Cultured Neurons
Cortical neurons were mixed with adenovirus at MOI of 50 prior to plat-
ing and were then immediately seeded to 24-well plates and cultured
for three days as previously described (Aleyasin et al., 2004; O’Hare
et al., 2005; Zhang et al., 2006). The cultures were exposed to MPP+
for 48 hr. Cultures were then fixed and stained with Hoechst 33258
(0.5 ng/ml) and neuronal survival was evaluated by assessing nuclear
integrity of GFP-positive neurons as previously described (Aleyasin
et al., 2004). For transfection, 3 days after plating cortical neurons
were transiently transfected using a modified calcium phosphate pre-
cipitation protocol (Xia et al., 1996; Zhang et al., 2006). In brief, neurons
were transfected with 1 mg of total plasmid DNA (0.75 mg of plasmid
DNA and 0.25 mg of pEGFP as a reporter) purified using an EndoFree
Plasmid Maxi kit (QIAGEN, Inc, Canada). Twenty-four hours post-
transfection, neurons were treated with 20 mM MPP+ (48 hr) and
were fixed in 4% paraformaldehyde (containing 0.2% picric acid in
0.1M phosphate buffer [pH 6.9]) and evaluated as described above.
Alternatively, neurons were transfected with double-stranded short-in-
terfering RNA (siRNA) to Prx2 or CY3-labeled control duplex (60 pmol
siRNA/24-well) as previously described (Zhang et al., 2006). We have
observed that targeting of duplexes to neurons is much more efficient
than that of plasmids and have used this procedure previously (Aleya-
sin et al., 2004; Zhang et al., 2006). The Prx2 duplexes (s1: GCUUUCG
GACUACAGAGGG, s2: GGGAUUCUUUAAGAGCUCU, s3: CCAAAU
AAUUACUAGGCCU) along with a Cy3-labeled control duplex were
obtained from Ambion (Austin, TX, USA). Forty-eight hours post-trans-
fection, neurons were treated with MPP+ (20 mM). At appropriate times,
the cells were assayed for survival by MTT method (48 hr) or ROS as
described above. Alternatively, cultures were analyzed by Western
blot analyses for Prx2 levels (24 hr).
Peroxidase Activity Assay
Peroxidase activity was carried out by measurement of the consump-
tion of NADPH (Fisher) which was mediated by Trx (Sigma, Canada)
and Trx reductase (Sigma, Canada) at 30C for 10 min for bacterially
expressed proteins and 1 hr for precipitated proteins from cultured
neurons or the SNc. In brief, 0.5 mg of bacterially expressed proteins
or the precipitated proteins was incubated with 5 mM Trx, 1 mM Trx
reductase, and 100 mM NADPH in HEPES (pH 7.5). The reaction was
initiated by the addition of H2O2 at a final concentration of 0.2 mM.
The consumption of NADPH was measured at 340 nm by spectropho-
tometer.
MPTP Administration
Mice received one intraperitoneal (i.p.) injection of MPTP$HCl per day
(25 mg of free base per kg of body weight per injection; Sigma) for 3 or
5 consecutive days (Crocker et al., 2001; Kalia et al., 2004; Kim et al.,
2005; Smith et al., 2003); control mice received an equivalent volume
of 0.9% saline. Brains were extracted at indicated times and eitherperfused for immunohistochemical analyses or quickly removed and
dissected for biochemical analyses.
Intrastriatal Administration of Adenoviruses
The adenoviruses expressing Prx2, Prx2T89A, and Prx2T89E were en-
gineered using pAdEasy system as previously described (Sedarous
et al., 2003). We and others have previously shown that adenoviruses
can target the SNc from the striatum by retrograde transport (Crocker
et al., 2001, 2003; Kalia et al., 2004; Kim et al., 2005; Smith et al., 2003).
Each adenovirus was injected directly into the striatum of animals
7 days before initiation of MPTP treatment (as described above). A
GFP-containing construct was used as a control. A single unilateral
injection of each virus (2 ml, 1 3 107 particles per ml) was delivered to
the right striatum (0.5 mm rostral, 2.2 mm right of bregma, and
3.4 mm below the skull surface). Each adenovirus injection was given
at a constant rate (0.5 ml/min) by using a syringe pump system. Brains
were extracted for immunohistochemistry and western blot analysis 14
days after the first MPTP treatment. Double-labeling experiments with
GFP (present in all viral vectors) and TH indicated that the majority of
SNc TH-positive neurons at the level of the medial terminal nucleus
were also GFP positive for all viruses injected (GFP control, Prx2,
Prx2T89A, and Prx2T89E).
Immunocytochemistry
Mice were perfused transcardially and brains were fixed in paraformal-
dehyde and cryoprotected as previously described (Crocker et al.,
2003). Serial coronal sections (14 mm thickness) of the ventral midbrain
were collected as free-floating sections in 0.01 M PBS/0.02% sodium
azide or collected on slides. Sections were then incubated in primary
antibody (to TH, 1:10,000; p-T89, 1:100, in 0.3% Triton X-100/0.01 M
PBS) for 24 hr at 4C. For TH staining on floating sections, slices
were then incubated with biotinylated secondary antibody and strep-
tavidin horseradish peroxidase-conjugated tertiary antibody and visu-
alized by using a 3,30-diaminobenzidine/glucose oxidase reaction as
previously described (Crocker et al., 2003). To examine the distribution
of phosphorylated Prx2 in DAergic neurons, a double-labeling immu-
nofluorescence approach was used. After incubation with the specific
primary antibody at 4C, immunolabeling was visualized by using ei-
ther Alex-488-conjugated anti-rabbit IgG (1:2000) or Alex-594-conju-
gated anti-mouse IgG (1:2000).
Quantification of DAergic Neuron Loss
The number of DAergic (TH-positive) neurons was only counted from
the sections in the region containing the medial terminal nucleus
(MTN) because this region has been previously shown to be expressed
at the highest level of virus-mediated gene expression after intrastriatal
infection (Crocker et al., 2001). We also used the MTN as a landmark to
evaluate consistent levels of the SNc. Neurons ipsilateral and contra-
lateral to the viral injection were assessed as described above in at
least three sections per animal. The number of neurons from ipsilateral
or contralateral was then counted as previously described. Alterna-
tively, cresyl violet staining was performed to validate determination
of nigral counts as previously described (Crocker et al., 2003).
Western Blot Analysis for the SNc
The western blot assay was performed as previously described (Smith
et al., 2003). In brief, 50 mg of protein was analyzed by SDS-PAGE
using antibodies to phospho-Prx2T89, Prx2, and b-actin.
Human Brain Samples
Paraffin-embedded blocks of postmortem human midbrain were
collected from the Ottawa Hospital Department of Pathology. Autop-
sies were performed according to the policies and procedures of
The Ottawa Hospital with consent from the next-of-kin. The tissue
was deparaffinized in xylene and subjected to citrate antigen retrieval
(Martins et al., 1999) prior to DAB staining. Diagnoses of PD were made
based on medical histories and postmortem confirmation (J.M.W.).Neuron 55, 37–52, July 5, 2007 ª2007 Elsevier Inc. 49
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Cdk5 Phosphorylation of Prx2 in Neuron LossThe mean average age for PD (n = 5; 4 males and 1 female) and control
patients (n = 6; 6 males) was 72.6 ± 3.7 and 72.5 ± 3.6, respectively,
and showed no significance (p < 0.986). Postmortem intervals for PD
and control samples did not differ significantly (p < 0.3).
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/55/1/37/DC1/.
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